Physician profile
Michael Einstein
NPI 1659339901
$138,574.40
in general payments reported to CMS, 2019-2025
49 companies · $29K in 2025
The $29K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $20K · 2021: $9,081 · 2022: $18K · 2023: $16K · 2024: $23K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Consulting Fee: $12K · Food and Beverage: $9,879 · Travel and Lodging: $5,311 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,102.00 |
| Consulting Fee | $11,510.00 |
| Food and Beverage | $9,879.45 |
| Travel and Lodging | $5,311.00 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $110,723.87 | 2019-2025 | Epclusa, Livdelzi, Vemlidy |
| Mirum Pharmaceuticals, INC. | $9,499.15 | 2024-2025 | Livmarli, Chenodal, Cholbam |
| Ipsen Biopharmaceuticals, INC | $7,349.91 | 2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,823.19 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,228.67 | 2019-2025 | |
| Janssen Biotech, INC. | $1,140.87 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $1,110.27 | 2019-2025 | Entyvio, Eohilia, Livtencity |
| Intercept Pharmaceuticals, INC. | $651.04 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $459.25 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $418.07 | 2021-2024 | Zeposia |
| Novo Nordisk INC | $364.66 | 2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $343.84 | 2023-2025 | Terlivaz |
| Ironwood Pharmaceuticals, INC | $294.29 | 2020-2025 | Linzess |
| Regeneron Healthcare Solutions, INC. | $259.20 | 2022-2024 | Dupixent |
| Ardelyx, INC. | $173.58 | 2023-2024 | Ibsrela |
Show all 48 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Einstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.